Shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) traded down 1% on Monday . The company traded as low as $10.11 and last traded at $10.38, with a volume of 301,286 shares traded. The stock had previously closed at $10.49.

The stock has a market cap of $518.37 million and a P/E ratio of 14.01. The firm has a 50 day moving average price of $11.02 and a 200-day moving average price of $11.64.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share for the quarter. The firm earned $39 million during the quarter, compared to analysts’ expectations of $37.90 million. On average, equities research analysts predict that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current fiscal year.

In other news, CEO Friedhelm Blobel sold 501,875 shares of the business’s stock in a transaction dated Wednesday, August 17th. The shares were sold at an average price of $10.00, for a total transaction of $5,018,750.00. Following the completion of the sale, the chief executive officer now owns 588,255 shares of the company’s stock, valued at $5,882,550. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Wilson Wai-Shun Cheung sold 7,802 shares of the business’s stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $10.62, for a total transaction of $82,857.24. Following the sale, the chief financial officer now directly owns 25,000 shares of the company’s stock, valued at approximately $265,500. The disclosure for this sale can be found here.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.